专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

EP2297359B1 GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES 有权
标题翻译：基因表达谱乳腺癌细胞紊乱的输出
公开(公告)号：EP2297359B1
公开(公告)日：2013-11-13
申请号：EP09770678.2
申请日：2009-06-01
申请人： The University of North Carolina at Chapel Hill , University of Utah Research Foundation , Washington University , British Columbia Cancer Agency Branch
发明人： PEROU, Charles, M. , PARKER, Joel, S. , MARRON, James, Stephen , NOBEL, Andrew , BERNARD, Philip, S. , ELLIS, Matthew , MARDIS, Elaine , NIELSEN, Torsten, O. , CHEANG, Maggie
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G06F19/20 , G06F19/24

82. 发明公开

EP2586445A1 Methods of facilitating cell survival using neurotrophin mimetics 审中-公开
标题翻译：神经营养因子-Mimetika Verfahren zurErmöglichungdesÜberlebensvon Nervenzellen mit Neurotrophin-Mimetika
公开(公告)号：EP2586445A1
公开(公告)日：2013-05-01
申请号：EP12191674.6
申请日：2006-04-03
申请人： UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL , U.S. Government represented by the Department of Veterans Affairs
发明人： Longo, Frank, M. , Massa, Stephen, M.
IPC分类号： A61K31/522 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/28
CPC分类号： A61K31/519 , A61K31/155 , A61K31/445 , A61K31/496 , A61K31/497 , A61K31/522 , A61K31/537 , C07K16/2878 , C07K2317/76
摘要： Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75 NTR receptor molecule. Enhanced survival of neural and other cells has been observed.
摘要翻译：用于治疗神经变性和其他疾病的方法和化合物。包括向有需要的受试者施用有效量的对p75NTR受体分子具有结合特异性的化合物。已经观察到增强神经元和其他细胞的存活。

83. 发明公开

EP2532739A3 Method of screening candidate compounds for susceptibility to biliary excretion 审中-公开
标题翻译：扫描候选化合物敏感性胆汁排泄
公开(公告)号：EP2532739A3
公开(公告)日：2013-03-27
申请号：EP12153422.6
申请日：2005-05-10
申请人： UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
发明人： Brouwer, Kim, L. , Tian, Xianbin , Zhang, Peijin
IPC分类号： G01N33/50 , C12N5/074
CPC分类号： G01N33/6872 , C12N5/067 , C12N2503/02 , C12N2510/00 , G01N33/5067
摘要： A method of screening a candidate compound for susceptibility to biliary excretion by a hepatocyte transport protein. The method includes the steps of providing a culture of hepatocytes comprising a transport protein, the culture having at least one bile canaliculus; exposing a candidate compound to the culture; and determining an amount of candidate compound in the at least one bile canaliculus, the amount of candidate compound in the at least one bile canaliculus indicating the susceptibility of the candidate compound to biliary excretion by the transport protein. In some embodiments determining the amount of candidate compound in the bile canaliculus comprises inhibiting expression of the transport protein, measuring the amount of candidate compound in the bile canaliculus and comparing amounts of compound in the canalicules with and without inhibition of the transport protein. A difference in the amount of candidate compound in the canaliculus indicates susceptibility of the candidate compound to biliary excretion by the transport protein. In one embodiment, expression of the transport protein is inhibited through introduction of a RNA having a sequence corresponding to a coding strand of the gene encoding the transport protein into the hepatocyte. Optionally, the culture of hepatocytes is a long-term culture in a sandwich configuration. The method is particularly applicable to the screening of multiple candidate compounds in a single effort.

84. 发明公开

EP2566567A1 METHOD OF ENGRAFTING CELLS FROM SOLID TISSUES 无效转让
标题翻译：方法移植细胞硬组织的
公开(公告)号：EP2566567A1
公开(公告)日：2013-03-13
申请号：EP11778410.8
申请日：2011-05-06
申请人： University of North Carolina at Chapel Hill
发明人： TURNER, Rachael , GERBER, David , LOZOYA, Oswaldo , REID, Lola, M.
IPC分类号： A61M31/00
CPC分类号： A61K35/407 , A61K9/0024 , A61K35/39 , A61K38/00 , A61K47/34 , A61K47/36 , A61L27/38 , A61L27/52 , A61L27/54 , A61L2300/414 , A61L2430/28 , C12N5/0672 , C12N2533/80 , C12N2537/10 , Y02A50/411 , A61K2300/00
摘要： A method of repairing diseased or dysfunctional organs or of establishing a model system of a disease state is provided. For repairing diseased organs, the method involves engraftment of cells from healthy tissue of the diseased or dysfunctional organ admixed with gel-forming biomaterials and nutrient medium, signaling molecules and extracellular matrix components that can be made insoluble rapidly upon transplantation to form a graft. In this way, the graft mimics the complexity of the native microenvironment with a minimum number of components that allow transplantation of cells to successfully engraft, expand and then rebuild part or the entirety of the diseased or dysfunctional organ. In the case of using grafting methods for establishing a disease model, diseased cells may be transplanted in the biomaterials and into experimental hosts.

85. 发明公开

EP2561353A1 PREDICTORS OF PHARMACOKINETIC AND PHARMACODYNAMIC DISPOSITION OF CARRIER-MEDIATED AGENTS 审中-公开
标题翻译：药物动力学和药物动力学配制载体介导剂的预测
公开(公告)号：EP2561353A1
公开(公告)日：2013-02-27
申请号：EP11772538.2
申请日：2011-04-19
申请人： The University Of North Carolina At Chapel Hill
发明人： ZAMBONI, William C. , CARON, Whitney Paige
IPC分类号： G01N33/48 , C12Q1/00
CPC分类号： C12Q1/02 , G01N33/5047 , G01N33/5091 , G01N2800/52
摘要： The invention provides a method of predicting the clearance rate of a carrier-mediated agent and/or the release of an agent from a carrier in a subject comprising measuring the number and/or activity of phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement within a biological sample obtained from a subject, and predicting the clearance rate of the carrier-mediated agent and/or the release of the agent from the carrier based upon the number and/or activity of the phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement. The invention also provides a method of predicting the activity of the reticuloendothelial (RES) system comprising measuring the number and/or activity of phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement in a biological sample obtained from a subject. The invention further provides a method of identifying a carrier-mediated agent having a desired effect on and/or interaction with the RES. Also provided is a method of selecting an appropriate animal model for preclinical studies of a carrier-mediated agent. The invention further encompasses methods of screening carrier-mediated agents for pharmacologic, efficacy and/or toxicologic effects, e.g., as part of an in vitro, ex vivo and/or in vivo system.
摘要翻译：本发明提供了预测受试者中载体介导的试剂的清除率和/或试剂从载体中的释放的方法，其包括测量吞噬细胞的数量和/或活性和/或量和/或活性调理素的量和/或补体的量和/或活性，以及基于所述载体介导的试剂的数量和/或活性来预测所述载体介导的试剂的清除率和/或所述试剂从所述载体的释放，或吞噬细胞的活性和/或调理素的量和/或活性和/或补体的量和/或活性。本发明还提供预测网状内皮（RES）系统活性的方法，包括测量吞噬细胞的数量和/或活性和/或调理素的量和/或活性和/或补体的量和/或活性在从受试者获得的生物样品中。本发明进一步提供了鉴定在RES上具有期望的作用和/或与RES相互作用的载体介导的药剂的方法。还提供了选择用于载体介导的药剂的临床前研究的合适动物模型的方法。本发明还包括筛选用于药理学，功效和/或毒理学作用的载体介导的试剂的方法，例如作为体外，离体和/或体内系统的一部分。

86. 发明公开

EP2537657A2 Methods and materials for fabricating microfluidic devices 审中-公开
标题翻译：方法和材料生产微流体装置的
公开(公告)号：EP2537657A2
公开(公告)日：2012-12-26
申请号：EP12185073.9
申请日：2006-08-09
申请人： The University of North Carolina at Chapel Hill , North Carolina State University
发明人： Desimone, Joseph, M , Rolland, Jason, P. , Rothrock, Ginger, M. Denison , Resnick, Paul
IPC分类号： B29C33/38 , C08L81/04 , C08L71/00
CPC分类号： B29C59/005 , B01L3/502707 , B01L2300/0887 , B01L2300/12 , B29C33/3878 , B29C33/405 , B29C65/48 , B29C65/4835 , B29C65/4845 , B29C65/485 , B29C65/521 , B29C66/54 , B29C66/543 , B29C66/71 , B29C66/723 , B29C66/727 , B29C66/91431 , B29C66/919 , B29C66/949 , B29C66/9534 , B29K2883/00 , B29L2031/756 , B81B2201/051 , B81C99/0085 , C08G18/10 , C08G18/5015 , C08G18/8175 , C08G59/30 , C08G65/007 , C08L71/02 , C08L75/16 , Y10T137/0318 , Y10T137/2224 , C08G18/50 , B29C65/00 , B29K2027/18 , B29K2027/12
摘要： Materials and methods are provided for fabricating microfluidic devices. The materials include low surface energy fluoropolymer compositions having multiple cure functional groups. The materials can include multiple photocurable and/or thermal-curable functional groups such that laminate devices can be fabricated. The materials also substantially do not swell in the presence of hydrocarbon solvents.

87. 发明公开

EP2535413A2 Splice switching oligomers for the TNF superfamily receptors and their use in treatment of disease 审中-公开
标题翻译：对于TNF超家族受体Spleißschaltende低聚物和它们在疾病治疗中使用
公开(公告)号：EP2535413A2
公开(公告)日：2012-12-19
申请号：EP12176988.9
申请日：2006-11-10
申请人： Santaris Pharma A/S , The University of North Carolina at Chapel Hill , Ercole Biotech, INC.
发明人： Sazani, Peter L. , Kole, Ryszard , Ørum, Henrik
IPC分类号： C12N15/113 , A61K31/712 , A61K31/7125 , C07H21/00 , A61P1/16 , A61P29/00 , A61P31/00
CPC分类号： C12N15/1138 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/346 , C12N2320/33 , C12N2310/3521
摘要： Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-α activity or activity of the relevant ligand. Reducing TNF- α activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-α activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H.
摘要翻译：方法和组合物是游离缺失盘在使用超家族化合物TNFR控制TNF受体（TNFR1和TNFR2）和其他受体的表达没有调节前mRNA编码受体论文的剪接。更具体地合成的化合物导致去除论文受体的跨膜结构域的，并产生用作拮抗剂以减少TNF±相关配体的活性或酶活性的受体的可溶性形式。减少TNF±活性提供了治疗或改善与TNF±活性相关的炎症性疾病或病症的方法。类似地，与其它配体相关的疾病可以以类似的方式进行处理。特别地，本发明的化合物是剪接的剪接转换寡聚物（的SSOs），它们是小分子并在体内是稳定，杂交以序列特异性方式与RNA，并且在结合它们的靶标，不被RNA酶H降解，

88. 发明公开

EP2497827A1 Micro-RNAs that regulate muscle cell proliferation and differentiation 审中-公开
标题翻译： Mikro-RNA miR-206 zur Regulierung der Muskelzell-Proliferation und Differenzierung
公开(公告)号：EP2497827A1
公开(公告)日：2012-09-12
申请号：EP12166173.0
申请日：2006-12-12
申请人： UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
发明人： Wang, Da-zhi , Chen, Jianfu
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： A61K31/7088 , C12N15/113 , C12N2310/113 , C12N2310/141 , C12N2310/321 , C12N2310/3517 , C12N2330/10 , C12N2310/3521
摘要： The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter.
摘要翻译：目前公开的主题提供了调节肌细胞中基因表达的方法和组合物。还提供了包含本发明的主题的组合物的细胞。

89. 发明公开

EP2484780A1 Methods and materials for determining pain sensibility and predicting and treating related disorders 审中-公开
标题翻译：的方法和材料用于测定疼痛敏感性的与预测和治疗相关病症的
公开(公告)号：EP2484780A1
公开(公告)日：2012-08-08
申请号：EP12000245.6
申请日：2005-07-25
申请人： The University of North Carolina At Chapel Hill
发明人： Diatchenko, Luda B. , Maixner, William , Slade, Gary D. , Nackley, Andrea Gail
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12N15/1137 , C12N15/1138 , C12N2310/14 , C12Q1/6881 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , C12Y201/01006 , G06F19/18 , Y02A90/24 , Y02A90/26
摘要： Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided.
摘要翻译：体感治疗病症和通过施用以有效量的COMT调制器的，ADRB2调制器，调制器ADRB3或组合的受试者中提供其调制促炎性细胞因子的方法。预测有效的药理学疗法，用于通过确定性采矿的病症体感关于选自COMT，ADRB2，ADRB3，以及它们的组合进一步提供了选择的基因的受试者的基因型折磨的受试者的方法。确定性采矿疼痛反应或疼痛感和主题的预测敏感性制定相关的疾病，：如躯体感觉障碍和躯体，以确定开采主体的基因型对于基因选自COMT，ADRB2，ADRB3的选择方法，和其组合是更提供。

90. 发明授权

EP1828390B1 CHIMERIC VECTORS 有权
标题翻译：嵌合载体
公开(公告)号：EP1828390B1
公开(公告)日：2012-06-13
申请号：EP05826631.3
申请日：2005-12-15
申请人： THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL , University of Florida Research Foundation, Incorporated
发明人： BOWLES, Dawn E. , LI, Chengwen , RABINOWITZ, Joseph E. , GRIEGER, Josh , AGBANDJE-MCKENNA, Mavis , SAMULSKI, Richard Jude
IPC分类号： C12N15/864 , C12N15/63 , C12N15/64 , C12N15/35 , C12N7/01 , A61K48/00
CPC分类号： C12N15/86 , C12N2750/14122 , C12N2750/14143 , C12N2750/14144
摘要： The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式